Broken String Biosciences

The INDUCE-seq™ platform is a game changing #technology for the development of advanced #therapies that are safer by design, but what is it? Watch this video to learn how the platform precisely characterizes and maps DNA double-strand breaks using Next Generation Sequencing. Leveraging a novel PCR-free approach, the platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to unlock new therapeutic targets within the genome and to advance gene editing programs. 🧪 #CellTherapy #GeneTherapy 

Our Director of Alliance Management Elisa Arthofer is attending the ESGCT Annual Congress this week. This conference is a vital gathering for the global gene and cell therapy community, bringing together leading experts, researchers, and industry professionals. Elisa will be exploring groundbreaking innovations and discussing how our DNA mapping technology, INDUCE-seq, can drive the development of safer and more effective gene-edited therapies. Connect with her on LinkedIn to set up a time to meet if you're also attending the ESGCT! We would love to meet you. #ESGCT2024 #GeneTherapy #CellTherapy #Innovation #Biotech #AllianceManagement

We're growing fast and looking for passionate, talented individuals to help us drive the future of precision medicine. If you're ready to make an impact in a dynamic and forward-thinking environment, we want to hear from you.   Current Open Roles: 1. Associate Director of Business Development, San Francisco, California 2. Senior Manufacturing Manager, Cambridge, East Anglia 3. Field Application Scientist, Boston, Massachusetts These roles offer a unique opportunity to work alongside leading experts in genomics, make meaningful contributions to groundbreaking projects, and grow your career in an innovative, fast-paced environment. Explore more and apply here: https://lnkd.in/eVpSqqEV Know someone who would be a perfect fit? Feel free to share or tag them in the comments! #Hiring #Genomics #Careers #Biotech

What an inspiring experience at the Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa! This year, we heard incredible stories, including Jimi Olaghere's—once a sickle cell patient, now a mountain climber. Jimi’s journey from battling this debilitating disease to conquering Mount Kilimanjaro showcases the transformative power of CRISPR-engineered therapies. His participation in a CRISPR gene-editing trial several years ago corrected the mutation behind his sickle cell disease, and with this groundbreaking therapy now approved in both the U.S. and Europe, countless others have new hope for a brighter future. Alongside these moving patient stories, our Chief Commercial Officer, Steve Becker and Elisa Arthofer, Director of Alliance Management, had the chance to connect with therapeutic developers and showcase our DNA mapping technology, INDUCE-seq. This cutting-edge platform enables the development of safer gene-edited therapies by reducing risk and saving time—accelerating the next wave of scientific breakthroughs in the field. We’re excited for the future of gene and cell therapies, and it's an honor to contribute to this innovative community!   #CellandGeneMesa #RegenerativeMedicine #GeneEditing #CRISPR #Mesa2024

It was a fantastic day 1 at the Meeting on The Mesa. The field is moving fast, exciting with challenges being solved, while others remain. Key conversations highlighted off target analysis as crucial for guide selection, kinetic studies, and IND enabling work. Positive feedback on our INDUCE-Seq® solutions' potential to address real-world challenges was encouraging. Elisa Arthofer, Director of Alliance Management, and I are having a great time meeting new friends and connecting with old ones. #CGT, #celltherapy, #genetherapy, #NGS, #Offtargetanalysis Broken String Biosciences

We're looking forward to seeing you at the Mesa next week. #CGMesa24 

Exciting advancements in genome editing tools like CRISPR-Cas9 are opening new doors for cell and gene therapies but ensuring their safe and effective use in patients requires rigorous pre-clinical assessments of off-target editing events. Precision in measuring these effects is critical to accelerating the development of these groundbreaking therapies. In this webinar hosted by Technology Networks, our Co-founder and CSO, Simon Reed, Ph.D. discusses the current challenges in off-target gene editing and explores how new technologies can help overcome these hurdles. He dives into the importance of precision in gene editing for Cell & Gene Therapy development and what the future holds for safer, more effective therapies. To watch the webinar on-demand, you may register here: https://lnkd.in/ecNCjeWV #GenomeEditing #CRISPR #GeneTherapy #PrecisionMedicine #CellTherapy #Webinar

I recently had the privilege of attending the ASGCT Policy Summit, and it’s evident that the industry is on the cusp of remarkable growth. With rapid scientific advancements progressing through the pipeline, we are closer than ever to addressing unmet medical needs. It’s especially encouraging to see strong engagement from various FDA divisions, working collaboratively with sponsors and policymakers. This type of cooperation is essential in transforming the vision of novel therapies—particularly for oncology and rare diseases—into reality. That said, there is still significant work ahead. Regulatory support, public policy development, and ensuring payer coverage and reimbursement remain critical areas of focus. As Rubin M., Director of Global Regulatory Affairs at Intellia Therapeutics, highlighted in his keynote, on/off-target editing analysis is a key consideration in regulatory approvals. Broken String Biosciences is well positioned to support our pharma partners in these regulatory discussions. The progress we’re witnessing as a community gives us hope that viable therapies are on the horizon. However, the journey is far from over. #ASGCTadvocacy #ASGCT #GeneTherapy #RareDisease #PolicySummit #FDA #Biotech #Innovation #HealthcareTransformation #Oncology

 Exciting News! We’re delighted to welcome Laurence Reid, Ph.D. as Chairman and Brad Crutchfield as Non-Executive Director to our Board of Directors. Their combined expertise in biotech and life sciences will be crucial as we continue to advance INDUCE-seq® and drive growth in the cell and gene therapy industry.   Read the full announcement here: https://lnkd.in/e9kc4WRf   #Leadership #Biotech #CellAndGeneTherapy #Innovation #BoardAnnouncement

In just under a month, our Director of Alliance Management, Elisa Arthofer, and Chief Commercial Officer, Steve Becker will be attending the Cell & Gene Meeting on the Mesa in Phoenix, AZ, from October 7-9, 2024! We’re excited to engage in meaningful discussions, explore collaboration opportunities, and showcase our latest breakthroughs in safe and effective genome editing technologies. Let’s meet at the Mesa to discuss how we can innovate together and create lasting impact. See you there! #CellAndGeneTherapy #GenomeEditing #Innovation #Mesa2024